Drug Trial Radar · NCT05786573
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
134
Planned (sponsor's estimate)
Start
Sep 25, 2023
Primary completion
Jun 30, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Zenas BioPharma (USA), LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).
Conditions
- Warm Autoimmune Hemolytic Anemia
Interventions
ObexelimabDrug
Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
ObexelimabDrug
Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Dose Confirmation Run-in Period (SRP)Time frame: 24 weeks
- Randomized Control Period (RCP)Time frame: 24 weeks
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Italy
Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii
Gdansk, Pomeranian Voivodeship, Poland
Hospital Universitario de Burgos
Burgos, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
National Cheng Kung University Hospital
Tainan, Taiwan
Plymouth Hospitals NHS Trust
Plymouth, Devon, United Kingdom
Kent and Canterbury Hospital
Canterbury, Kent, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.